ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

Since their introduction, drug formularies and formulary systems have gone through many changes. However, at present, even greater changes are underway as a result of the reorganisation of the US healthcare system. They are no longer simply a means of adding, deleting or restricting the use of drugs, but are one of several appropriate-use strategies that can be used to standardise the quality of drug use and to assist in the management of medical outcomes. The evolution of hospital formularies and ways to develop, refine and implement effective appropriate-use programmes were presented during the 1996 Annual Meeting of the American Society of Health-System Pharmacists [San Diego, US; June 1996].

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

Last week,Inpharma® reviewed the use of aldose reductase inhibitors and glycosylation antagonists in the treatment of diabetic complications, as discussed during the 2nd International Conference on ‘Diabetic Complications as Drug Targets’*[London, UK; May 1996]. In this week's issue, the review continues with one of the recent ‘misses’ of research in this field, levacecarnine [acetyl-L-carnitine; ST-200]. The role of neurotrophins and growth factors in the development of diabetic complications are also reviewed, along with their potential as targets for treatment.

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS